Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 4.90
ALIOF's Cash to Debt is ranked higher than
64% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. ALIOF: 4.90 )
ALIOF' s 10-Year Cash to Debt Range
Min: 2.7   Max: N/A
Current: 4.9

Equity to Asset 0.72
ALIOF's Equity to Asset is ranked higher than
75% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. ALIOF: 0.72 )
ALIOF' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.72
Current: 0.72

0.5
0.72
Interest Coverage 58.07
ALIOF's Interest Coverage is ranked higher than
53% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALIOF: 58.07 )
ALIOF' s 10-Year Interest Coverage Range
Min: 0.3   Max: 9999.99
Current: 58.07

0.3
9999.99
F-Score: 7
Z-Score: 14.55
M-Score: -2.36
WACC vs ROIC
8.91%
63.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 30.29
ALIOF's Operating margin (%) is ranked higher than
96% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. ALIOF: 30.29 )
ALIOF' s 10-Year Operating margin (%) Range
Min: 0.68   Max: 29.11
Current: 30.29

0.68
29.11
Net-margin (%) 31.22
ALIOF's Net-margin (%) is ranked higher than
96% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. ALIOF: 31.22 )
ALIOF' s 10-Year Net-margin (%) Range
Min: -8.15   Max: 30.33
Current: 31.22

-8.15
30.33
ROE (%) 33.55
ALIOF's ROE (%) is ranked higher than
98% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. ALIOF: 33.55 )
ALIOF' s 10-Year ROE (%) Range
Min: -8.85   Max: 53.58
Current: 33.55

-8.85
53.58
ROA (%) 23.73
ALIOF's ROA (%) is ranked higher than
98% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. ALIOF: 23.73 )
ALIOF' s 10-Year ROA (%) Range
Min: -5.18   Max: 21.05
Current: 23.73

-5.18
21.05
ROC (Joel Greenblatt) (%) 125.13
ALIOF's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. ALIOF: 125.13 )
ALIOF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 2.31   Max: 174.15
Current: 125.13

2.31
174.15
Revenue Growth (3Y)(%) 3.70
ALIOF's Revenue Growth (3Y)(%) is ranked higher than
77% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. ALIOF: 3.70 )
ALIOF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -25.8   Max: 21.5
Current: 3.7

-25.8
21.5
EBITDA Growth (3Y)(%) 131.30
ALIOF's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ALIOF: 131.30 )
ALIOF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -48.4   Max: 131.3
Current: 131.3

-48.4
131.3
» ALIOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ALIOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.40
ALIOF's P/E(ttm) is ranked higher than
95% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 24.40 )
ALIOF' s 10-Year P/E(ttm) Range
Min: 13.52   Max: 66.51
Current: 24.4

13.52
66.51
Forward P/E 19.65
ALIOF's Forward P/E is ranked higher than
99% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 19.65 )
N/A
PE(NRI) 24.00
ALIOF's PE(NRI) is ranked higher than
96% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 24.00 )
ALIOF' s 10-Year PE(NRI) Range
Min: 13.54   Max: 66.51
Current: 24

13.54
66.51
P/B 7.60
ALIOF's P/B is ranked higher than
58% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. ALIOF: 7.60 )
ALIOF' s 10-Year P/B Range
Min: 2.35   Max: 7.6
Current: 7.6

2.35
7.6
P/S 7.80
ALIOF's P/S is ranked higher than
79% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. ALIOF: 7.80 )
ALIOF' s 10-Year P/S Range
Min: 1.96   Max: 16.68
Current: 7.8

1.96
16.68
PFCF 26.10
ALIOF's PFCF is ranked higher than
96% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 26.10 )
ALIOF' s 10-Year PFCF Range
Min: 8.65   Max: 2760
Current: 26.1

8.65
2760
POCF 24.43
ALIOF's POCF is ranked higher than
95% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 24.43 )
ALIOF' s 10-Year POCF Range
Min: 8.43   Max: 240
Current: 24.43

8.43
240
EV-to-EBIT 22.03
ALIOF's EV-to-EBIT is ranked higher than
96% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 22.03 )
ALIOF' s 10-Year EV-to-EBIT Range
Min: -53.3   Max: 261.7
Current: 22.03

-53.3
261.7
PEG 1.63
ALIOF's PEG is ranked higher than
99% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 1.63 )
ALIOF' s 10-Year PEG Range
Min: 0   Max: 4.8
Current: 1.63

0
4.8
Shiller P/E 46.10
ALIOF's Shiller P/E is ranked higher than
95% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 46.10 )
ALIOF' s 10-Year Shiller P/E Range
Min: 30.5   Max: 46.1
Current: 46.1

30.5
46.1
Current Ratio 2.74
ALIOF's Current Ratio is ranked higher than
64% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ALIOF: 2.74 )
ALIOF' s 10-Year Current Ratio Range
Min: 1.75   Max: 3.95
Current: 2.74

1.75
3.95
Quick Ratio 2.66
ALIOF's Quick Ratio is ranked higher than
66% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ALIOF: 2.66 )
ALIOF' s 10-Year Quick Ratio Range
Min: 1.7   Max: 3.8
Current: 2.66

1.7
3.8
Days Inventory 104.79
ALIOF's Days Inventory is ranked higher than
89% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 104.79 )
ALIOF' s 10-Year Days Inventory Range
Min: 88.91   Max: 123.11
Current: 104.79

88.91
123.11

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.00
ALIOF's Dividend Yield is ranked higher than
53% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. ALIOF: 1.00 )
ALIOF' s 10-Year Dividend Yield Range
Min: 0.93   Max: 2.7
Current: 1

0.93
2.7
Dividend Payout 0.22
ALIOF's Dividend Payout is ranked higher than
98% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 0.22 )
ALIOF' s 10-Year Dividend Payout Range
Min: 0.47   Max: 1.14
Current: 0.22

0.47
1.14
Dividend growth (3y) 14.50
ALIOF's Dividend growth (3y) is ranked higher than
87% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 12.10 vs. ALIOF: 14.50 )
ALIOF' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 14.5
Current: 14.5

0
14.5
Yield on cost (5-Year) 1.00
ALIOF's Yield on cost (5-Year) is ranked lower than
53% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 1.38 vs. ALIOF: 1.00 )
ALIOF' s 10-Year Yield on cost (5-Year) Range
Min: 0.93   Max: 2.7
Current: 1

0.93
2.7
Share Buyback Rate 0.70
ALIOF's Share Buyback Rate is ranked higher than
97% of the 990 Companies
in the Global Biotechnology industry.

( Industry Median: -9.90 vs. ALIOF: 0.70 )
ALIOF' s 10-Year Share Buyback Rate Range
Min: 1.7   Max: -81.8
Current: 0.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 39.00
ALIOF's Price/Net Cash is ranked higher than
59% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 220.30 vs. ALIOF: 39.00 )
ALIOF' s 10-Year Price/Net Cash Range
Min: 11.79   Max: 75.62
Current: 39

11.79
75.62
Price/Net Current Asset Value 36.40
ALIOF's Price/Net Current Asset Value is ranked higher than
57% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. ALIOF: 36.40 )
ALIOF' s 10-Year Price/Net Current Asset Value Range
Min: 4.58   Max: 21.66
Current: 36.4

4.58
21.66
Price/Tangible Book 11.20
ALIOF's Price/Tangible Book is ranked higher than
56% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. ALIOF: 11.20 )
ALIOF' s 10-Year Price/Tangible Book Range
Min: 2.98   Max: 10.28
Current: 11.2

2.98
10.28
Price/DCF (Projected) 3.30
ALIOF's Price/DCF (Projected) is ranked higher than
95% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 3.30 )
ALIOF' s 10-Year Price/DCF (Projected) Range
Min: 1.41   Max: 2.85
Current: 3.3

1.41
2.85
Price/Median PS Value 2.30
ALIOF's Price/Median PS Value is ranked higher than
68% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. ALIOF: 2.30 )
ALIOF' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 4.47
Current: 2.3

0.57
4.47
Price/Graham Number 3.50
ALIOF's Price/Graham Number is ranked higher than
94% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 3.50 )
ALIOF' s 10-Year Price/Graham Number Range
Min: 1.4   Max: 3.02
Current: 3.5

1.4
3.02
Earnings Yield (Greenblatt) 4.40
ALIOF's Earnings Yield (Greenblatt) is ranked higher than
93% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. ALIOF: 4.40 )
ALIOF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 13.3
Current: 4.4

0.4
13.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:ATLNE.Switzerland, ATLN.Switzerland, ACT.Germany, 0QMN.UK,
Actelion Ltd was founded on December 17, 1997 and is headquartered in Allschwil, Switzerland. The Company is a biopharmaceutical company, that engages in the discovery, development, and commercialization of low molecular weight drugs for unmet medical needs. It is engaged in the field of pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Its products portfolio includes Opsumit (Macitentan), Tracleer (Bosentan), Valchlor (Mechlorethamine), Zavesca (Miglustat), Veletri (Epoprostenol For Injection), and Ventavis (Iloprost).
» More Articles for ALIOF

Headlines

Articles On GuruFocus.com
Actelion Still On Growth Track Feb 18 2015 

More From Other Websites
Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog May 22 2015
Kite Pharma Starts Dosing in Phase I/II Study on KTE-C19 - Analyst Blog May 22 2015
Bristol-Myers' HCV Combination Designation Amended by FDA - Analyst Blog May 21 2015
Regeneron-Sanofi's Sarilumab Meets Endpoints in Phase III - Analyst Blog May 21 2015
Intercept Pharmaceuticals Reveals Phase III OCA Study Plan - Analyst Blog May 20 2015
Sarepta to Finish Eteplirsen Regulatory Filing by Mid-15 - Analyst Blog May 20 2015
Eleven Biotherapeutics Tanks after Eye Drug Fails Study - Analyst Blog May 19 2015
Regeneron/Sanofi Announce Positive Data on Dupilumab - Analyst Blog May 19 2015
Theravance Biopharma Posts Positive Data on Velusetrag - Analyst Blog May 19 2015
Genomic Health's Loss Lingers, Profits Expected in 4Q15 - Analyst Blog May 19 2015
XBiotech's Xilonix Recommended for Colorectal Cancer Study - Analyst Blog May 19 2015
Lannett (LCI) Signs Deal to Acquire Silarx Pharmaceuticals - Analyst Blog May 19 2015
Celgene/Accelreon's Luspatercept Granted Fast Track Status - Analyst Blog May 19 2015
Merck KGaA Q1 Earnings Fall Y/Y, 2015 Sales View Retained - Analyst Blog May 19 2015
MannKind (MNKD) in Focus: Stock Rises 10.1% in Session - Tale of the Tape May 19 2015
AstraZeneca Reports Data from KODIAC studies on Movantik - Analyst Blog May 18 2015
Astellas' Myrbetriq for Overactive Bladder Efficient as Add-On - Analyst Blog May 18 2015
AbbVie's Humira Gets FDA Orphan Status for Skin Disease - Analyst Blog May 18 2015
Kite Pharma Narrows Q1 Loss, Misses Estimates; Gives View - Analyst Blog May 18 2015
Amgen Announces Positive Results on Migraine Candidate - Analyst Blog May 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK